VE-821isapotentandselectiveATPcompetitiveinhibitorofataxia-telangiectasiaandRad3-relatedprotein(ATR)withIC50of26nMincell-freeassays,withminimalactivityagainstATM,DNA-PK,andmTOR.ItaugmentsDNAdamageandcelldeathofcancercellsinresponsetor
ADIation,alsosensitizescancercellstochemotherapy.
ProductName: | VE-821 |
---|
AlsoKnownAs: | 3-Amino-6-[4-(methylsulfonyl)phenyl]-N-phenyl-2-pyrazinecarboxamide |
---|
CatalogNo.: | F8131 |
---|
Size: | 25mg |
---|
CAS: | 1232410-49-9 |
---|
Formula: | C18H16N4O3S |
---|
MolecularWeight: | 368.41Da |
---|
Form: | Lyophilizedpowder |
---|
QualityAssurance: | >98%byHPLCandNMR |
---|
Source: | Synthetic |
---|
Storage: | EligIBLeforroomtemperatureshipping.Storeat-80°Cuponreceiving |
---|
PDFDataSheet: | DownloadPDFdatasheet |
---|
Image(s): | N/A |
---|
ShippingMethod: | Roomtemperatureshipping |
---|
References: | 1.ReaperPM,etal.(2011)NatChemBiol,7(7),428-430. 2.Prevo,R,etal.(2012)CancerBiolTher,13(11)1072-1081. 3.Huntoon,CJ,etal.(2013)CancerRes,73(12)3683-3691. |
---|
Details
VE-821isapotentandselectiveATPcompetitiveinhibitorofataxia-telangiectasiaandRad3-relatedprotein(ATR)withIC50of26nMincell-freeassays,withminimalactivityagainstATM,DNA-PK,andmTOR.ItaugmentsDNAdamageandcelldeathofcancercellsinresponsetoradiation,alsosensitizescancercellstochemotherapy.
Solubility:
20mg/mlinDMSO
泛素-蛋白酶体生物技术有限公司(UBPBio),LLC是一家私有公司,由科学家和投资人于2011年成立。UBPBio致力于为学术界和工业界提供高质量的试剂,以加快对泛素-蛋白酶体系统及相关途径的发现。 。目前,我们的产品线包括16个类别,提供350多种产品。如果您在泛素领域需要特殊试剂,请与我们联系,我们将竭诚为您服务。